Our study suggests that MeCP2 up‐regulated epithelial markers, such as E‐cadherin, and that MeCP2 knockdown in breast cancer cell lines increased mesenchymal biomarkers, such as Vimentin. The gene discussed is CDH1; the disease is breast cancer.